Previous Page
NanoViricides, Inc. (OTC BB: NNVC) has retained Australian Biologics Pty. Ltd., a regulatory affairs consulting firm, to coordinate the regulatory review and approval to conduct the first human trials in Australia for Flucide(TM), the Company’s broad-spectrum anti-influenza drug. Australian Biologics will also facilitate clinical trial site(s) selection and development of the clinical trials agreements. The Company believes that it will have the capability for producing drugs suitable for human clinical trials when renovation of the new facility in Shelton is completed. In parallel, the Company continues to pursue appropriate human clinical study pathways for its highly effective anti-influenza drug candidate, NV-INF-1, in the FluCide™ program. The Company has engaged Australian Biologics to study and develop a roadmap for conducting certain Phase 1 and Phase 2 human clinical studies in Australia. NV-INF-1 has been shown to be highly effective in controlling influenza viral infection in lethal infection mouse model. Animals survived for full duration of the study (21 days) when treated with NV-INF-1 on alternate days. In contrast, oseltamivir-treated animals (40mg/kg given every day) survived for only 8 days. Untreated animals survive only 5 days in this highly lethal influenza infection model. The Company has previously reported that depending upon the treatment protocol, NV-INF-1 has shown viral load reduction of 1.3 logs to 3 logs in these various studies. In contrast, oseltamivir (Tamiflu(R)) treatment in the same studies has resulted in viral load reductions of only about 0.2 logs to 0.8 logs.
CEA Liten (France), Innovation Lab (Germany) and the University of Sheffield (UK) have each independently selected and purchased Aerosol Jet deposition systems. The systems are used for the development of next-generation technologies for electronic sensors and displays, 3D conformal electronic devices, fuel cells and solar cells, and other emerging printed electronics applications. With the addition of these marquee industrial labs, the total number of Optomec users in Europe now exceeds 40 leading institutions and corporations. Innovation Lab GmbH (iL) is an application-oriented organization for research and knowledge transfer in science and business. Innovation Lab is located in the Rhine-Neckar metropolitan region, and is supported by the Universities of Heidelberg and Mannheim, and by the companies BASF SE, Merck KGaA, Freudenberg & Co., Heidelberger Druckmaschinen AG, Roche Diagnostics GmbH and SAP AG.
P2i has received the title of "Outstanding New Product/Service" for its innovative development of the Aridion(TM) liquid repellent nano-coating tech- nology for high volume manufacturing.